NEW YORK, Jan. 12 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
In collaboration with analysts from The Healthcare business unit, in this brief Ovum's Pharmaceutical Technology team outlines the key changes in the pharma industry, explains which trends will have the biggest impact, and analyses the implications and opportunities of these developments for both pharmaceutical companies and providers of technologies and services.
*This brief outlines business issues and technology enablers that are expected to affect the pharmaceutical industry during 2010.
*The report covers developments in North America and Europe.
Through research and analysis, Ovum has identified several key trends that will shape the pharma and biotech markets in 2010. Pharma is evolving towards a new business model: Pharma 2.0, new R&D models embrace biotechnology and biomedical research and the future success of pharma relies on the emerging markets.
As the life sciences industry moves into its next phase, technology will play a significant role in its transformation. However, in the short term, there will be some solutions that will take precedence over others.
Reasons to Purchase
*Understand the key operational trends to watch during 2010.
*Gain insight into the technologies that pharmaceutical companies must either invest in or extract more value from in 2010.
OVUM VIEW 2
BUSINESS TRENDS AND TECHNOLOGY ENABLERS 4
PHARMA IS EVOLVING TOWARDS A NEW BUSINESS MODEL: PHARMA 2.0 5
Innovative R&D marries business process with technology 6
New sales and marketing models focus on engaging with all stakeholders 7
External collaboration on R&D will enhance drug discovery 8
NEW R&D MODELS EMBRACE BIOTECHNOLOGY AND BIOMEDICAL RESEARCH 9
M&A helps biotech companies survive the funding crisis 10
Governments support biotech research 11
THE FUTURE SUCCESS OF PHARMA RELIES ON THE EMERGING MARKETS 11
The emerging markets provide ample M&A opportunities, but tread carefully 11
Outsourcing is a crucial strategy for making the Pharma 2.0 company leaner 12
TECHNOLOGY RECOMMENDATIONS FOR ORGANISATIONS IN THE LIFE SCIENCES SECTOR 13
Streamline R&D operations by breaking down silos and increasing internal communication 13
Collaborate and partner with non-traditional stakeholders 13
Be creative in developing new sales and marketing strategies 13
RECOMMENDATIONS FOR PROVIDERS OF TECHNOLOGIES AND SERVICES 14
Educate life sciences companies on the benefits of pharma-specific commercial IT solutions 14
Cater to the emerging markets in order to see rapid growth 15
Focus on technology solutions that enable the shift towards personalised medicine 15
FURTHER READING 16
LEAD AUTHOR 17
CONTRIBUTING AUTHOR 17
OVUM CONSULTING 17
List of Figures
Figure 1: The evolution of the traditional pharma model to Pharma 2.0 5
Figure 2: The pharma product lifecycle aligning business processes with technology solutions 7
Figure 3: The underlying need for collaboration across the pharma lifecycle and where IT fits in 9
To order this report:
Intl: +1 805-652-2626